Mass screening for CD36 antigen expression and analysis of negative donor structure and supply capacity
10.13303/j.cjbt.issn.1004-549x.2025.05.004
- VernacularTitle:CD36抗原表达大规模筛查及阴性供者结构与供能分析
- Author:
Yunping XU
1
;
Tangrui XIONG
2
;
Fan YANG
2
;
Wenxia XIA
2
;
Ximiao LI
1
;
Huatao CHE
1
;
Zhilei LI
3
Author Information
1. Shenzhen Blood Center, Institution of Transfusion Medicine, Shenzhen 518000, China
2. Sichuan University, Chendu 610065, China
3. Department of Pharmacy, Southern University of Science and Technology Hospital, Shenzhen 518055, China
- Publication Type:Journal Article
- Keywords:
apheresis platelet;
CD36 antigen expression;
CD36 deficiency;
flow cytometry;
blood group distribution
- From:
Chinese Journal of Blood Transfusion
2025;38(5):615-620
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To establish a database of CD36 antigen-negative donors through large-scale screening of apheresis platelet donors in Shenzhen for CD36 deficiency subtypes and blood group distribution, and to assess clinical demand and blood supply capacity through a retrospective analysis of the apheresis platelet donation volumes from 2019 to 2023. Methods: Flow cytometry with fluorescent CD36 monoclonal antibodies was employed to screen platelet/monocyte CD36 deficiency (Type I and Ⅱ), and statistical analyses were conducted using SPSS software (version 27.0). Results: Among 11 603 apheresis platelet donors, 248 (2.14%) exhibited CD36 deficiency, comprising 51 type Ⅰ (0.43%, 51/11, 603) and 197 type Ⅱ (1.70%, 197/11, 603) cases, with significant difference (P<0.001). CD36 deficient platelets were mainly distributed in blood group B (2.28%, 902.3/39 602.1) and AB (2.14, 269/12 544.5), significantly exceeding those in blood group A (1.43%, 667/46 508.4) and O (1.64%, 1 000/60 965.6) (P<0.001). The proportion of donors with 10-100 U from CD36 deficient donors was the highest (51%, 1 446.4/2 838.3). Conclusion: Sustained screening for CD36-deficient donors is recommended to meet the clinical transfusion needs for immunized patients and those requiring antigen-negative products. Regional resource-sharing mechanisms should be optimized to maximize utilization of CD36-deficient platelet inventories.
